Matches in SemOpenAlex for { <https://semopenalex.org/work/W2364307578> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2364307578 endingPage "8C" @default.
- W2364307578 startingPage "3C" @default.
- W2364307578 abstract "This prospective. single open-label sludy was conducted in 14 Canadian centres to assess lhe efncacy of I g, once a day intravenous ceftriaxone treatment administered for a minimum of three days in patients with lower respiratory tract infection. There were 137 patients enrolled. Age varied between 19 and 95 years (mean 68 years). Mosl patients (91 %) were diagnosed with community acquired pneumonia without bacteremia. Most of the cases (82%) were defined as modcralc or severe. Patients received ceftriaxone treatment for an average or five days. Macrolidcs or metronidazole were administered concomitantly wilh ceftriaxone in 34 patienls (25%). After a minimum of three days of ceftriaxone treatment. 59 palicnls (43%) were switched to oral antibiotics. Favourable treatment outcome was found in 92.9% and treatment failure (including relapse of infection) in 7.1 % o lpalicnls. Evaluable patients accounted for 91 % of patients enrolled in the study. Clinical cure and clinical improvement were achieved in 64.6 and 28.3% of the evaluable patients. respectively. Relapse of infection occurred in two patients (1.8%). and treatment failure was recorded in six cases (5.3%). Twelve patients (8.8%) died clue to reasons unrelated to the sludy treatment. Three adverse event (hives, diarrhea and phlebitis at the injection site) were possibly related to the study drug. A cross-Canada in vitro susceptibility surveillance study of bacterial pathogens. frequently the cause of pneumonia. found ceftriaxone to have minimal inhibitory concentrations in 90% of isolates that would support such a dosing regimen. with the exception of Enterobacter species. These rcsults support the use of 1 g, once daily ceftriaxone for the empirical treatment of pneumonia in those patients requiring hospitalization." @default.
- W2364307578 created "2016-06-24" @default.
- W2364307578 creator A5065701017 @default.
- W2364307578 creator A5072357134 @default.
- W2364307578 date "1994-01-01" @default.
- W2364307578 modified "2023-09-24" @default.
- W2364307578 title "A Prospective Open-Label Multicentre Trial on the Use of 1 G, Once Daily Ceftriaxone in Lower Respiratory Tract Infections" @default.
- W2364307578 doi "https://doi.org/10.1155/1994/421905" @default.
- W2364307578 hasPublicationYear "1994" @default.
- W2364307578 type Work @default.
- W2364307578 sameAs 2364307578 @default.
- W2364307578 citedByCount "3" @default.
- W2364307578 crossrefType "journal-article" @default.
- W2364307578 hasAuthorship W2364307578A5065701017 @default.
- W2364307578 hasAuthorship W2364307578A5072357134 @default.
- W2364307578 hasBestOaLocation W23643075782 @default.
- W2364307578 hasConcept C126322002 @default.
- W2364307578 hasConcept C141071460 @default.
- W2364307578 hasConcept C188816634 @default.
- W2364307578 hasConcept C197934379 @default.
- W2364307578 hasConcept C2776012195 @default.
- W2364307578 hasConcept C2776520383 @default.
- W2364307578 hasConcept C2777396551 @default.
- W2364307578 hasConcept C2777914695 @default.
- W2364307578 hasConcept C2779443120 @default.
- W2364307578 hasConcept C2779802037 @default.
- W2364307578 hasConcept C2781413609 @default.
- W2364307578 hasConcept C501593827 @default.
- W2364307578 hasConcept C534529494 @default.
- W2364307578 hasConcept C71924100 @default.
- W2364307578 hasConcept C86803240 @default.
- W2364307578 hasConcept C89423630 @default.
- W2364307578 hasConceptScore W2364307578C126322002 @default.
- W2364307578 hasConceptScore W2364307578C141071460 @default.
- W2364307578 hasConceptScore W2364307578C188816634 @default.
- W2364307578 hasConceptScore W2364307578C197934379 @default.
- W2364307578 hasConceptScore W2364307578C2776012195 @default.
- W2364307578 hasConceptScore W2364307578C2776520383 @default.
- W2364307578 hasConceptScore W2364307578C2777396551 @default.
- W2364307578 hasConceptScore W2364307578C2777914695 @default.
- W2364307578 hasConceptScore W2364307578C2779443120 @default.
- W2364307578 hasConceptScore W2364307578C2779802037 @default.
- W2364307578 hasConceptScore W2364307578C2781413609 @default.
- W2364307578 hasConceptScore W2364307578C501593827 @default.
- W2364307578 hasConceptScore W2364307578C534529494 @default.
- W2364307578 hasConceptScore W2364307578C71924100 @default.
- W2364307578 hasConceptScore W2364307578C86803240 @default.
- W2364307578 hasConceptScore W2364307578C89423630 @default.
- W2364307578 hasIssue "suppl c" @default.
- W2364307578 hasLocation W23643075781 @default.
- W2364307578 hasLocation W23643075782 @default.
- W2364307578 hasOpenAccess W2364307578 @default.
- W2364307578 hasPrimaryLocation W23643075781 @default.
- W2364307578 hasRelatedWork W191342243 @default.
- W2364307578 hasRelatedWork W1966465453 @default.
- W2364307578 hasRelatedWork W1996306145 @default.
- W2364307578 hasRelatedWork W2001151927 @default.
- W2364307578 hasRelatedWork W2015863095 @default.
- W2364307578 hasRelatedWork W2018473564 @default.
- W2364307578 hasRelatedWork W2029978358 @default.
- W2364307578 hasRelatedWork W2031406265 @default.
- W2364307578 hasRelatedWork W2034651578 @default.
- W2364307578 hasRelatedWork W2073147091 @default.
- W2364307578 hasRelatedWork W2097462342 @default.
- W2364307578 hasRelatedWork W2126897182 @default.
- W2364307578 hasRelatedWork W2341935310 @default.
- W2364307578 hasRelatedWork W2401748477 @default.
- W2364307578 hasRelatedWork W2405647843 @default.
- W2364307578 hasRelatedWork W2412024993 @default.
- W2364307578 hasRelatedWork W2417325992 @default.
- W2364307578 hasRelatedWork W2898344418 @default.
- W2364307578 hasRelatedWork W98221040 @default.
- W2364307578 hasRelatedWork W2183683598 @default.
- W2364307578 hasVolume "5" @default.
- W2364307578 isParatext "false" @default.
- W2364307578 isRetracted "false" @default.
- W2364307578 magId "2364307578" @default.
- W2364307578 workType "article" @default.